All above suggest that the molecular mechanism of anticancer agents interacting with Ras/Raf/MEK/ERK pathway is still unclear in NSCLC, and there is a very pressing need to identify and exploit new chemotherapy for NSCLC patients. Here, RAF1 is linked to non-small cell lung carcinoma.